Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20500111 | 0.89 | SRC (0.65) | SRCCSNK1A1CSNK1DCSNK1ERET | |
| SCHEMBL20500101 | 0.88 | SRC (0.62) | SRCCSNK1A1CSNK1DCSNK1ERET | |
| SCHEMBL863906 | 0.88 | SRC (0.64) | SRCCSNK1A1CSNK1DCSNK1ERET | |
| SCHEMBL20744772 | 0.86 | SRC (0.60) | SRCCSNK1A1CSNK1DCSNK1ERET | |
| SCHEMBL20744781 | 0.86 | SRC (0.60) | SRCCSNK1A1CSNK1DCSNK1ERET | |
| SCHEMBL20744798 | 0.86 | SRC (0.60) | SRCCSNK1A1CSNK1DCSNK1ERET | |
| SCHEMBL20744784 | 0.86 | SRC (0.60) | SRCCSNK1A1CSNK1DCSNK1ERET | |
| SCHEMBL20744770 | 0.86 | SRC (0.60) | SRCCSNK1A1CSNK1DCSNK1ERET | |
| SCHEMBL20500096 | 0.81 | CSNK1A1 (0.62) | SRCCSNK1A1CSNK1DCSNK1ERET | |
| SCHEMBL20744808 | 0.81 | SRC (0.55) | SRCCSNK1A1CSNK1DCSNK1ERET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518761-B2 | CDPK1 inhibitors, compositions, and methods related thereto | Vyera Pharmaceuticals, LLC (US) | 2022-12-06 | — | — | US | disclosed |
| US-20210347780-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC | 2021-11-11 | — | — | US | disclosed |
| US-20210032240-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC | 2021-02-04 | — | — | US | disclosed |
| EP-3668875-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036001-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036001-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347780-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | CAMKK1, CAMK1, CAMKK2 | SRC 408/4885CSNK1A1 19/4885CSNK1D 170/4885 |
| US-11518761-B2 | CDPK1 inhibitors, compositions, and methods related thereto | CAMKK1, CAMK1, CAMKK2 | SRC 408/4885CSNK1A1 19/4885CSNK1D 170/4885 |
| US-20210032240-A1 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | CAMKK1, CAMK1, CAMKK2 | SRC 408/4885CSNK1A1 19/4885CSNK1D 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.